Opdivo is projected to lead the growth in renal cell carcinoma (RCC) market and be a market leader by 2023, according to a report by GlobalData.

Titled ‘PharmaPoint: Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2023‘, the report details how the data obtained from recently conducted trials have strengthened Opdivo’s position as an efficient drug for the treatment of metastatic renal cell carcinoma (mRCC).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The promising outlook for the drug is backed by encouraging survival outcome rates and objective response rates.

The drug is expected to have a high-patient uptake and consequently transform the RCC market, which is currently dominated by tyrosine kinase inhibitors and mTOR inhibitors.

"The drug is expected to have a high-patient uptake and consequently transform the RCC market, which is currently dominated by tyrosine kinase inhibitors and mTOR inhibitors."

A recent finding regarding Bristol-Myers Squibb’s Opdivo was presented at the American Society of Clinical Oncology conference held in May this year. The findings have labelled the drug as a new standard of care for mRCC.

See Also:

The GlobalData report forecasts that the RCC market will expand to $3.6bn by 2023 from $2.1bn in 2013 mainly driven by the success of Opdivo. The recent trials measured the efficacy of Opdivo over its competitor Afinitor and have indicated a comparatively better tumour response with Opdivo, which is a positive finding as tumour response is correlated with patient survival.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results of Phase I and II trials indicate that the survival of patients treated with the drug is promising in the long-term.

Dan Roberts, Ph.D., GlobalData’s senior analyst covering oncology and hematology, says: "These long-term results support the initial data published in the New England Journal of Medicine in September 2015, and further demonstrate that Opdivo significantly improves survival with a good quality-of-life."